Illumina Innovation Fund II GP, L.L.C. bought $4.0M of ALMR
owner at Alamar Biosciences, Inc.. 235,294 shares at an average of $17.00, traded Apr 20, 2026, filed Apr 20, 2026.
Score components
- +12Role10% owner
- +25Trade size$4.0M at market
- +10Relative to holdingsHoldings up 87%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.4%, 3m +8.7%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-164634, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | CConversion Class B Common Stockindirect: See footnote | +4,588,364 | - | - | 4,588,364 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Class B Common Stockindirect: See footnote | +922,152 | - | - | 5,510,516 | Apr 20, 2026 |
| Apr 20, 2026 | JOther Class B Common Stockindirect: See footnote | -5,510,516 | - | - | 0 | Apr 20, 2026 |
| Apr 20, 2026 | JOther Common Stockindirect: See footnote | +5,510,516 | - | - | 5,510,516 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Common Stockindirect: See footnote | +346,020 | - | - | 5,856,536 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Common Stockindirect: See footnote | +271,782 | - | - | 271,782 | Apr 20, 2026 |
| Apr 20, 2026 | POpen-market purchase Common Stockindirect: See footnote | +235,294 | $17.00 | $4.0M | 507,076 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Series A-3 Preferred Stockderivativeindirect: See Footnote | -3,194,377 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Series A-4 Preferred Stockderivativeindirect: See Footnote | -2,862,507 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Series B Preferred Stockderivativeindirect: See Footnote | -2,094,266 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Series C Preferred Stockderivativeindirect: See Footnote | -5,037,783 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Convertible Promissory Notederivativeindirect: See Footnote | - | $0.00 | - | 0 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Convertible Promissory Notederivativeindirect: See Footnote | - | $0.00 | - | 0 | Apr 20, 2026 |
Related signals
Other insiders at Alamar Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | Alamar Biosciences, Inc. | Nicholas Naclerio director | $4.0M 235,294 shares | +87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.